Author Correction: Combination therapy targeting Erk1/2 and CDK4/6i in relapsed refractory multiple myeloma

Affiliations

¹ Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, 02215, USA. sophia_adamia@dfci.harvard.edu.
² Dana-FArber Cancer Institute, Harvard Medical School, Boston, MA, 02215, USA.
³ Department of Pharmacy, National University of Singapore, Singapore, 117559, Singapore.
⁴ Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, 02215, USA.
⁵ Department of Data Science, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.
⁶ Ilia State University, School of Medicine, Tbilisi, G409, Georgia.
⁷ Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 02215, USA.
⁸ Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, 02215, USA. kenneth_anderson@dfci.harvard.edu.

Published Erratum

Sophia Adamia et al. Leukemia. 2022 Jun.

. 2022 Jun;36(6):1700.

doi: 10.1038/s41375-022-01588-z.

¹ Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, 02215, USA. sophia_adamia@dfci.harvard.edu.
² Dana-FArber Cancer Institute, Harvard Medical School, Boston, MA, 02215, USA.
³ Department of Pharmacy, National University of Singapore, Singapore, 117559, Singapore.
⁴ Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, 02215, USA.
⁵ Department of Data Science, Dana-Farber Cancer Institute, Boston, MA, 02215, USA.
⁶ Ilia State University, School of Medicine, Tbilisi, G409, Georgia.
⁷ Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 02215, USA.
⁸ Jerome Lipper Multiple Myeloma Disease Center, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, 02215, USA. kenneth_anderson@dfci.harvard.edu.

No abstract available

Erratum for

Combination therapy targeting Erk1/2 and CDK4/6i in relapsed refractory multiple myeloma.
Adamia S, Bhatt S, Wen K, Chyra Z, Fell GG, Tai YT, Pioso MS, Abiatari I, Letai A, Dorfman DM, Hideshima T, Anderson KC. Adamia S, et al. Leukemia. 2022 Apr;36(4):1088-1101. doi: 10.1038/s41375-021-01475-z. Epub 2022 Jan 27. Leukemia. 2022. PMID: 35082402 Free PMC article.